Advances in the Prevention of Cervical Cancer by Anti-Human Papillomavirus Agents

IF 3.1 2区医学 Q2 ONCOLOGY Cancer Medicine Pub Date : 2025-04-06 DOI:10.1002/cam4.70847

Hangdi Chen, Kai Guo, Zhihao Bai, Liuyi Lu, Bin Liu, Jiali Zhang, Meiyin Zhong, Changfen Xu, Wanghuan Chen, Aiwu Huang, Yuemin Ding

{"title":"Advances in the Prevention of Cervical Cancer by Anti-Human Papillomavirus Agents","authors":"Hangdi Chen, Kai Guo, Zhihao Bai, Liuyi Lu, Bin Liu, Jiali Zhang, Meiyin Zhong, Changfen Xu, Wanghuan Chen, Aiwu Huang, Yuemin Ding","doi":"10.1002/cam4.70847","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Cervical cancer remains a major global health threat for women, primarily driven by human papillomavirus (HPV) infection. While HPV vaccination serves as the cornerstone of prevention, disparities in vaccine accessibility persist across low-income countries. Secondary prevention through screening faces challenges in public engagement, often leading to late-stage diagnoses. Recent advancements in novel anti-HPV drugs offer expanded opportunities for cervical cancer management.</p>\n </section>\n \n <section>\n \n <h3> Aim</h3>\n \n <p>This review examines emerging anti-HPV therapeutics to provide insights into innovative strategies for cervical cancer prevention and treatment.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We conducted a systematic analysis of published studies investigating anti-HPV agents, focusing on their molecular mechanisms and clinical efficacy in cervical cancer prevention.</p>\n </section>\n \n <section>\n \n <h3> Results & Conclusions</h3>\n \n <p>Multiple promising anti-HPV agents have been identified, including 3-hydroxyphthalic anhydride-modified bovine β-lactoglobulin (3HP-β-LG), carrageenan, defensins, and 25-hydroxycholesterol (25HC). These compounds exert antiviral effects through distinct mechanisms: 3HP-β-LG competitively inhibits viral attachment, carrageenan blocks HPV entry via heparan sulfate mimicry, defensins inhibit the dissociation of viral capsid, and 25HC activates cholesterol-mediated antiviral pathways. They have demonstrated strong inhibitory effects on HPV infection, making them novel therapeutic candidates for the prevention and treatment of cervical cancer.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 7","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70847","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70847","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Cervical cancer remains a major global health threat for women, primarily driven by human papillomavirus (HPV) infection. While HPV vaccination serves as the cornerstone of prevention, disparities in vaccine accessibility persist across low-income countries. Secondary prevention through screening faces challenges in public engagement, often leading to late-stage diagnoses. Recent advancements in novel anti-HPV drugs offer expanded opportunities for cervical cancer management.

Aim

This review examines emerging anti-HPV therapeutics to provide insights into innovative strategies for cervical cancer prevention and treatment.

Methods

We conducted a systematic analysis of published studies investigating anti-HPV agents, focusing on their molecular mechanisms and clinical efficacy in cervical cancer prevention.

Results & Conclusions

Multiple promising anti-HPV agents have been identified, including 3-hydroxyphthalic anhydride-modified bovine β-lactoglobulin (3HP-β-LG), carrageenan, defensins, and 25-hydroxycholesterol (25HC). These compounds exert antiviral effects through distinct mechanisms: 3HP-β-LG competitively inhibits viral attachment, carrageenan blocks HPV entry via heparan sulfate mimicry, defensins inhibit the dissociation of viral capsid, and 25HC activates cholesterol-mediated antiviral pathways. They have demonstrated strong inhibitory effects on HPV infection, making them novel therapeutic candidates for the prevention and treatment of cervical cancer.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

抗人乳头瘤病毒药物预防宫颈癌的研究进展

背景宫颈癌仍然是全球妇女面临的主要健康威胁，其主要诱因是人类乳头瘤病毒（HPV）感染。虽然 HPV 疫苗接种是预防宫颈癌的基石，但在低收入国家，疫苗接种的可及性仍然存在差距。通过筛查进行的二级预防在公众参与方面面临挑战，往往导致晚期诊断。新型抗 HPV 药物的最新进展为宫颈癌的治疗提供了更多机会。目的本综述探讨新兴的抗 HPV 治疗方法，为宫颈癌预防和治疗的创新策略提供见解。方法我们对已发表的抗 HPV 药物研究进行了系统分析，重点关注其在宫颈癌预防中的分子机制和临床疗效。结果 & 结论已发现多种有前景的抗 HPV 药物，包括 3- 羟基邻苯二甲酸酐修饰的牛β-乳球蛋白（3HP-β-LG）、卡拉胶、防御素和 25- 羟基胆固醇（25HC）。这些化合物通过不同的机制发挥抗病毒作用：3HP-β-LG 竞争性地抑制病毒附着，角叉菜胶通过硫酸肝素模拟阻断 HPV 进入，防御素抑制病毒荚膜解离，25HC 激活胆固醇介导的抗病毒途径。它们对人类乳头瘤病毒感染有很强的抑制作用，因此成为预防和治疗宫颈癌的新型候选疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.